[PDF] hanspub.org

[PDF][PDF] Research progress of TCM combined with EGFR-TKI drugs in the treatment of advanced non-small cell lung cancer

WT Guo, WZ Shou - Adv Clin Exp Med, 2020 - pdf.hanspub.org
… 本文将对皮细胞生长因子受体(epidermal growth factor receptor, EGFR)酪氨酸激酶抑制剂(tyrosine
kinase inhibitor, TKI)类药物的研究进展,中医药联 合靶向治疗的临床研究进行综合阐述,为…
被引用次数：1 相关文章
[PDF] hanspub.org

[PDF][PDF] Research progress of multidrug resistance mechanism and reversal agents in breast cancer

J Yuan, X Zhu, YA Xu, Y Zhou - Adv Clin Med, 2019 - pdf.hanspub.org
… The treatment of breast cancer is mainly based on drug therapy, including chemotherapy …
EGFR (epidermal growth factor receptor, EGFR/HER-1)酪氨酸激酶抑制剂厄洛替尼(erlotinib)和…
被引用次数：2 相关文章
[PDF] hanspub.org

[PDF][PDF] Synergistic cytotoxic effect of anti-EGFR/gelonin immunotoxin combined with taxol a anti-tumor effects and its mechanism

NY Huang, XK Zhou, J Qiu, Z Wang, J Li - World J Cancer Res, 2014 - pdf.hanspub.org
… treatment of A549 tumor xenografts. The ELISA results showed the low concentration of EGFR
of serum and ECF in nude mice treated … 表皮生长因子受体(epithelial growth factor receptor…
被引用次数：1 相关文章 所有 3 个版本

Gefitinib plus Fuzheng Kang'ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: a …

X Yang, X Chai, W Wu, S Long, H Deng, Z Pan… - Chinese journal of …, 2018 - Springer
… Randomized phase Ⅱ study of erlotinib plus tivantinib versus erlotinib plus placebo in
previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-3015. …
被引用次数：21 相关文章 所有 7 个版本
[HTML] nih.gov

[HTML][HTML] 厄洛替尼致间质性肺病4 例并文献复习

吴小玲， 高广辉， 任胜祥， 周彩存 - Chinese Journal of Lung …, 2012 - ncbi.nlm.nih.gov
… Erlotinib is an agent of oral epidermal growth factor receptor (EGFR) tyrosine kinase …
erlotinib treatment and after corticosteroid treatment. A: Chest CT scan before erlotinib treatment…
被引用次数：7 相关文章 所有 3 个版本
[PDF] jebm.cn

[PDF][PDF] Erlotinib 治疗晚期非小细胞肺癌的综合研究

李进， 王坤， 徐崇锐， 张华 - 循证医学, 2004 - jebm.cn
… A review of smallrmolecule epidermal growth factor receptorrspecific tyrosine kinase
inhibitors in development for nonrsmall cell lung cancer [J]. Semin Oncol, 2004, 31(1 Suppl 1):…
相关文章 所有 3 个版本

西妥昔单抗或埃罗替尼治疗中皮肤副作用的描述和处理: 一项30 例患者的前瞻性研究

王琼 - 世界核心医学期刊文摘: 皮肤病学分册, 2006 - cqvip.com
… or erlotinib, which inhibit the epidermal growth factor receptor, are increasingly being used in
treatment … in patients with cancer treated with cetuximab or erlotinib. Methods: We clinically …
相关文章

间充质干细胞恶性分化及诱导癌细胞化疗耐受的机制研究

杨玥 - 2020 - ir.lzu.edu.cn
… cells to Erlotinib, which … to Erlotinib treatment. Mechanism studies show that MSCs enhance
AKT and ERK1/2 phosphorylation in HCC827 cells by secreting hepatocyte growth factor (…
相关文章 所有 2 个版本

[引用][C] Efficacy of gefitinib, erlotinib and icotinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation

RN Cong, F Gu, B Wang - J Mod Oncol, 2018
被引用次数：1 相关文章

[引用][C] The value analysis of blood brain barrier permeability in the treatment of multiple brain metastases patients with non-small cell lung cancer

Z Yongli, D Jigang, L Bo, L Maojiang, C Yan… - J. Mod. Oncol, 2017
被引用次数：1 相关文章